Associated Papers
Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.
Lo Schiavo F et al.
Molecular Cancer, 2025
Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
Hu C et al.
Cell Communication and Signaling : Ccs, 2024
Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.
Mirza Z et al.
International Journal of Molecular Sciences, 2024
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.
Ge SS et al.
Frontiers in Oncology, 2022
Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
Nishida Y et al.
Leukemia, 2021
Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia.
Wang A et al.
Haematologica, 2021
Deciphering the molecular mechanism of FLT3 resistance mutations.
Georgoulia PS et al.
The Febs Journal, 2020
First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations.
Daver N et al.
Frontiers in Oncology, 2020
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies.
Kennedy VE et al.
Frontiers in Oncology, 2020
Insights Into the Resistance Mechanisms of Inhibitors to FLT3 F691L Mutation via an Integrated Computational Approach.
Sun Y et al.
Frontiers in Pharmacology, 2019
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D et al.
International Journal of Molecular Sciences, 2018
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.
Jiang X et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K et al.
Annals of Hematology, 2016
FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.
Ma HS et al.
Cancer Research, 2014
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations.
Yu C et al.
Plos One, 2014
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
Opatz S et al.
Blood, 2013
The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.
Pauwels D et al.
Haematologica, 2012
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E et al.
British Journal of Haematology, 2012
Investigational drugs targeting FLT3 for leukemia.
Ustun C et al.
Expert Opinion on Investigational Drugs, 2009
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N et al.
Cancer Research, 2009
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK et al.
Experimental Hematology, 2007
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
Lierman E et al.
Haematologica, 2007
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J et al.
Cancer Research, 2004